Medically reviewed by Jurairat J. Molina, MD Acute urticaria (hives) is a common skin condition that affects up to 20% of people at some point in their lives. It can transition into chronic urticaria ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

1 Only 19.5% of patients reported they sometimes forget to take their medication ... therapy for both acute and chronic urticaria, some patients need additional treatment to find relief.

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Celldex Therapeutics is a pre-revenue biotechnology company focusing on developing treatments for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). The company's lead ...

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...

but can now point to a win for rilzabrutinib in chronic spontaneous urticaria (CSU). In a phase 2 trial, rilzabrutinib has been shown to rapidly reduce itch severity and significantly improve ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...